APA (7th ed.) Citation

Tereshchenko, S. N., Shestakova, M. V., Ageev, F. T., Galstyan, G. R., Galyavich, A. S., Glezer, M. G., . . . Matskeplishvili, S. T. Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement. «FIRMA «SILICEA» LLC.

Chicago Style (17th ed.) Citation

Tereshchenko, S. N., et al. Rationale for Dapagliflozin Administration for the Prevention of Adverse Outcomes in Patients with Heart Failure with Reduced Ejection Fraction. Expert Consensus Statement. «FIRMA «SILICEA» LLC.

MLA (9th ed.) Citation

Tereshchenko, S. N., et al. Rationale for Dapagliflozin Administration for the Prevention of Adverse Outcomes in Patients with Heart Failure with Reduced Ejection Fraction. Expert Consensus Statement. «FIRMA «SILICEA» LLC.